点击蓝字 关注我们投资要点投资要点•事件:6月4日公司宣布FIC每日一次口服小分子FASN抑制剂地尼法司他(ASC40)治疗中重度寻常性痤疮的III期临床试验达到所有主要、关键次要及次要终点。经安慰剂校准后的治疗成功率,地尼法司他(18.6%)疗效比FDA批准的沙瑞环素(9.4%)和多西环素(6.7%)分别高98%和178%。与FDA批准的柯拉特龙乳膏(11.6%)相比高60%。•目前痤疮疗法...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.